Aspire Biopharma Holdings (ASBP) Cash from Investing Activities (2021 - 2023)

Aspire Biopharma Holdings (ASBP) has reported Cash from Investing Activities for 3 consecutive years, with $632968.0 the latest figure, recorded in Q3 2023.

• On a quarterly basis, Cash from Investing Activities changed N/A year-over-year to $632968.0 in Q3 2023; TTM through Dec 2023 was $632968.0, a 100.21% increase from a year earlier, with the FY2024 full-year figure at $13.8 million, down 95.16% from the prior year.
• Cash from Investing Activities was $632968.0 for Q3 2023 at Aspire Biopharma Holdings, up from -$294.7 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $632968.0 in Q3 2023 and troughed at -$294.7 million in Q1 2022.
• A 3-year average of -$98.0 million and a median of $165955.0 in 2021 frame the typical range for Cash from Investing Activities.
• The widest YoY moves for Cash from Investing Activities: up 177670.73% in 2022, down 177670.73% in 2022.
• Over 3 years, Cash from Investing Activities stood at $165955.0 in 2021, then sank by 177670.73% to -$294.7 million in 2022, then jumped by 100.21% to $632968.0 in 2023.
• The last three Cash from Investing Activities figures came in at $632968.0 (Q3 2023), -$294.7 million (Q1 2022), and $165955.0 (Q1 2021), per Business Quant data.